The company plans a clinical trial for its CIL001 tinnitus drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET. Cilcare , a French-US biopharmaceutical company, announced a series of investments in the United States, including plans for a clinical trial of its tinnitus drug candidate, CIL001, and a significant expansion of its preclinical research...
No actionable change; CIL001 is a drug candidate just entering US clinical trials and is years away from any approved clinical use.
Tinnitus has no FDA-approved pharmacological treatment, making any credible drug entering human trials a significant milestone for the field.
- 01Cilcare is launching a US clinical trial for its tinnitus drug candidate CIL001 at Massachusetts General Hospital.
- 02The company is tripling its preclinical research capacity through a partnership with CBSET.
- 03CIL001 is still in early clinical stages — no efficacy or safety data in humans has been released.
- 04Tinnitus affects an estimated 15% of the global population and lacks approved drug treatments.
- 05Reported by Hearing Review, a trade publication, not a peer-reviewed source.
Cilcare is conducting a US clinical trial for CIL001 at Massachusetts General Hospital.
press releasesupportedCilcare plans to triple its preclinical research capacity through its partnership with CBSET.
press releasesupported